Kymera Therapeutics to Relocate from Cambridge to Watertown Biotech Cluster

WATERTOWN, September 26, 2019 – Boylston Properties, a Boston-based real estate developer of distinctive places, today announced that Kymera Therapeutics has signed a lease for approximately 34,500 square feet at Arsenal Yards‘ new state-of-the-art life science lab space. With the Charles River and Arsenal Park on its south side and energized shops and restaurants on its north side, the life science lab space is set within an original 1800s Arsenal historic building, offering a number of amenities and a private shuttle to the Harvard Square red line T stop.

 

Life science companies are flocking to Watertown to secure space in the town’s booming biotech scene. Kymera Therapeutics continues this trend, joining SQZ Biotech in moving to Arsenal Yards’ life science lab space. The new development is located across the street from LINX, 185,000 square feet of currently fully leased lab space, also developed by Boylston Properties.

 

“Given the state-of-the-art amenities and proximity to life science’s biggest names and talent, Watertown is now a first choice for life science companies,” said Bill McQuillan, Principal of Boylston Properties. “We’re proud to welcome Kymera Therapeutics to the Watertown life science cluster and look forward to supporting their continued growth. We are thankful to have worked alongside the great commercial real estate professionals at Cushman & Wakefield and Newmark to be able to welcome another cutting-edge life science company to Arsenal Yards.”

 

Kymera Therapeutics will relocate from Cambridge to East End Watertown in the first half of 2020. Founded in 2016, Kymera Therapeutics Inc. is a biotechnology company pioneering the field of targeted protein degradation, a transformative new approach to develop medicines for diseases with limited or no treatment options.

 

“Kymera is developing a company for the future. We were interested in a work environment that could grow with us and support our mission, fostering collaboration and productivity as we expand our programs and team. Arsenal Yards checked all of those boxes and has demonstrated a commitment to supporting a thriving and growing life sciences community,” said Nello Mainolfi, PhD, Founder, President & Chief Scientific Officer at Kymera Therapeutics. “We’re thrilled to start our next chapter in Watertown.”

 

Kymera Therapeutics was represented by Juliette Reiter and Mark Winters of Newmark. Boylston Properties was represented by Duncan Gratton and Elizabeth Donatoni of Cushman & Wakefield.

 

“Boylston Properties is paving the way for a booming life science and healthcare cluster in Watertown with the development of Arsenal Yards, and this is apparent as we’ve now closed deals with eight life science companies in Watertown, totaling approximately 300,000 square feet,” said Duncan Gratton, Executive Director at Cushman & Wakefield. “Watertown is more than Kendall Square overflow, it’s becoming its own urban neighborhood that attracts top talent with its amenities, proximity to Boston and Cambridge, and its best-in-class life science lab development.”

 

With initial openings planned for late 2019 and throughout 2020, Arsenal Yards will be a thriving new neighborhood comprised of over one million sq. ft. of development by 2021. The mixed used development will include 250,000 sq. ft. of shopping, dining and fitness, a seven-screen cinema, The Majestic at Arsenal Yards, fresh groceries from local grocer Roche Bros., 300 contemporary apartments and a 146-room Hampton Inn by Hilton. Learn more at www.arsenalyards.com.

 

ABOUT BOYLSTON PROPERTIES 

Boylston Properties is a Boston-based real estate developer of mixed-use places including retail, residential, hotel, corporate, and life science lab buildings. With four decades of experience and a contemporary vision, their distinctive projects have become part of Greater Boston’s new urban landscape. For more information, please visit www.boylstonproperties.com.

 

ABOUT CUSHMAN & WAKEFIELD

Cushman & Wakefield (NYSE: CWK) is a leading global real estate services firm that delivers exceptional value for real estate occupiers and owners. Cushman & Wakefield is among the largest real estate services firms with approximately 51,000 employees in 400 offices and 70 countries. In 2018, the firm had revenue of $8.2 billion across core services of property, facilities and project management, leasing, capital markets, valuation and other services. To learn more, visit www.cushmanwakefield.com or follow @CushWake on Twitter.

 

ABOUT KYMERA THERAPEUTICS

Kymera Therapeutics is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Powered by Pegasus™, a game-changing integrated degradation platform, Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. For more information visit, www.kymeratx.com.

By |2019-09-26T11:33:26-04:00September 26th, 2019|In the News, News|